Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.

FP008 is designed for patients with solid tumors that have not responded to existing immunotherapies targeting PD-1.

NEW YORK, March 04, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hu ...

The FDA’s clinical hold has prompted a cautious response from investors, reflecting the heightened regulatory scrutiny that BioNTech now faces. The company’s immediate focus will be on resolving the ...

The FDA approved the investigational new drug application for a phase 1 trial of ADCE-T02 in advanced solid tumors.

Proprietary Invisicare Delivery Technology Designed to Optimize Local Skin Penetration The proprietary Invisicare delivery technology, which Quoin has exclusive rights to for all orphan rare skin ...

Tiziana Life Sciences (NASDAQ:TLSA) rises after the company said it is planning the submission of its Investigational New ...

New EU Clinical Trial Regulations simplify international trials while offering the means to counter drug shortages for trials ...

BioRestorative Therapies, Inc. ("BioRestorative”, "BRTX” or the "Company”) (NASDAQ:BRTX), a clinical stage regenerative ...

Trumbull’s bill is aiming to tap into the significant potential of stem cell therapies in advancing medical treatments and ...

Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...